Search clinical trials for: BRAF V600E/K mutation

Total 3580 results

Melanoma Institute Australia

Active, not recruiting

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma (Neo Combi)

Melanoma

Australia
Novartis Pharmaceuticals

Completed

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (COMBI-AD)

Melanoma

United States, Belgium, Canada, Spain, United Kingdom, Netherlands, Argentina, Australia, Austria, Brazil, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, New Zealand, Norway, Poland, Russian Federation, Sweden, Switz... and more
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Anaplastic Thyroid Cancer | ATC

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Cancer

France, Spain, Netherlands, Canada, Austria, United States, Germany, Italy, Japan, Norway, Korea, Republic of, Denmark, Sweden, Belgium
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

CRC

China
xCures
Cancer Commons

Available

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Melanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditions

United States
Pfizer

Completed

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Melanoma and Metastatic Colorectal Cancer

United States, Spain, France, Japan, Australia, Switzerland, Norway
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation

Langerhans Cell Histiocytosis | Erdheim-Chester Disease | LCH | ECD

China
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation

Metastatic Colorectal Cancer | mCRC

China
Intergroupe Francophone de Cancerologie Thoracique

Completed

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings

Carcinoma, Non-Small-Cell Lung | KRAS Gene Mutation | ALK Gene Mutation | BRAF Gene Mutation

France
Hoffmann-La Roche

Completed

Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma

Metastatic Cancers

Spain
Revolution Medicines, Inc.
Sanofi

Completed

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Solid Tumor

United States, Korea, Republic of
Rennes University Hospital
QIAGEN Gaithersburg, Inc

Completed

cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project (KitMel)

Melanoma

France
Memorial Sloan Kettering Cancer Center
Array BioPharma

Completed

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Melanoma

United States
Jinsong Wu

Completed

Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid Detection

Glioma, Malignant

China
Pierre Fabre Medicament
Biotrial

Completed

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Melanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

France
Revolution Medicines, Inc.
Sanofi; Amgen

Active, not recruiting

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Canada, Taiwan, Spain, United Kingdom, Italy, Australia, France, Germany
Royal Cornwall Hospitals Trust
Biocartis

Completed

KEBI-Cyto Study - Use of the Biocartis Idylla

Pancreatic Adenocarcinoma | Lung Cancer

United Kingdom
Pierre Fabre Medicament

Withdrawn

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Hepatic Impairment | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

Spain, Czechia, Italy
Karen-Lise Garm Spindler

Completed

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - (OPTIPAL-II)

Colorectal Cancer Metastatic | KRAS Gene Mutation | Circulating Tumor DNA | BRAF Gene Mutation | NRAS Gene Mutation | Epidermal Growth Factor Receptor Inhibitor

Denmark
Pierre Fabre Medicament
Clinact

Completed

A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) (CAPSTAN CRC)

Metastatic Colorectal Cancer | BRAF V600E Mutation Positive

France, United Kingdom, Spain, Belgium, Germany, Italy, Austria
Intergroupe Francophone de Cancerologie Thoracique
Novartis

Completed

BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation (BLaDE)

Non Small Cell Lung Cancer | BRAF V600 Mutation

France
University Hospital Tuebingen

Terminated

Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study

Metastatic Melanoma (Carrying BRAF V600 Mutation)

Germany
Sunnybrook Health Sciences Centre

Active, not recruiting

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Melanoma

Canada
National Cancer Institute (NCI)

Active, not recruiting

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditions

United States
Spirita Oncology, LLC
University of Arizona

Terminated

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

Brain Metastases | Malignant Melanoma

United States
University of Heidelberg Medical Center
German Cancer Research Center; University Hospital Heidelberg; Array BioPharma; Coordinating Centre for Clinical Trials Heidelberg

Active, not recruiting

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) (GMMG-BIRMA)

Relapsed or Refractory Multiple Myeloma | Patients With BRAFV600 E or BRAFV600K Mutation

Germany
Novartis Pharmaceuticals

Completed

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Cancer

United States, United Kingdom, Japan, Norway, Spain, Taiwan, France, Germany, Korea, Republic of, Italy, Netherlands
National Cancer Institute (NCI)

Terminated

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Novartis Pharmaceuticals

Completed

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Melanoma | Cancer

Taiwan, Thailand, China, Hong Kong, Korea, Republic of
Intergruppo Melanoma Italiano

Active, not recruiting

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

BRAF V600 Mutation | Melanoma Metastatic

Italy
Pierre Fabre Medicament
Biotrial

Active, not recruiting

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Melanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

France
Novartis Pharmaceuticals

Completed

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Neoplasms, Brain

United States, France, Germany, Israel, Canada, Australia, Denmark, Spain, United Kingdom, Italy
MelanomaPRO, Russia
Crocus Medical B.V.

Completed

Advanced Melanoma in Russian Experience (ADMIRE)

BRAF V600 Mutation | Cutaneous Melanoma, Stage IV

Russian Federation
Gustave Roussy, Cancer Campus, Grand Paris

Active, not recruiting

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE)

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

France
National Human Genome Research Institute (NHGRI)

Completed

Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

BRAF V600E Mutation

United States
Canadian Cancer Trials Group
Novartis

Terminated

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Melanoma | Brain Metastases

Canada
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Recurrent Melanoma | Stage IV Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Withdrawn

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

Erdheim-Chester Disease

United States
Novartis Pharmaceuticals

Completed

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Melanoma

Canada, Spain, United Kingdom, Netherlands, United States, Argentina, Australia, France, Germany, Greece, Italy, Russian Federation, Sweden, Ukraine
Prof. Dr. med. Dirk Schadendorf

Completed

Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (IMMU-TARGET)

Malignant Melanoma

Germany
Clinigen, Inc.
Prometheus Laboratories

Terminated

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma (PROCLIVITY01)

Metastatic Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | BRAF Gene Mutation

United States
Hoffmann-La Roche

Completed

An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

Neoplasms

France, Hungary, Spain, Korea, Republic of, United Kingdom, United States, Croatia, Greece, Portugal, Germany, Bosnia and Herzegovina, Belgium, South Africa, Israel, Romania, New Zealand, Italy, Canada, Netherlands, Egypt, Russian... and more
UNC Lineberger Comprehensive Cancer Center
Bayer

Completed

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

United States, Ireland
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline

Completed

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma | BRAF Mutant Melanoma

United States
TriHealth Inc.
TriHealth Cancer Institute; TriHealth Surgical Institute; TriHealth Ultrasound... and other collaborators

Withdrawn

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Melanoma (Skin) | Tumor Skin | BRAF Gene Mutation | Melanoma Stage IIIb-IVM1a | Metastasis Skin

United States
Prof. Dr. med. Dirk Schadendorf

Terminated

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma (BOTTOM)

Malignant Melanoma

Germany
West Cancer Center
Amgen; University of Tennessee Health Science Center

Unknown

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

Melanoma | BRAF Gene Mutation

United States
Memorial Sloan Kettering Cancer Center

Completed

Continued Access to RXDX-105

Ovarian Cancer | Non Small Cell Lung Cancer | RET Gene Mutation | BRAF Gene Mutation

United States

Search clinical trials for: BRAF V600E/K mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations